<?xml version="1.0" encoding="utf-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
>

<channel rdf:about="http://www.biochemj.org">
<title>BJ Metabolism Immediate Publications</title>
<link>http://www.biochemj.org</link>
<description>Biochemical Journal RSS feed -- BJ Metabolism Immediate Publications</description>
<prism:issn>0264-6021</prism:issn>
<prism:eIssn>1470-8728</prism:eIssn>
<prism:publicationName>Biochemical Journal</prism:publicationName>
<items>
 <rdf:Seq>
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110765" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112124" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111478" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111057" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111881" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112026" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111748" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111509" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111530" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111280" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111648" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111420" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111849" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112037" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111796" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111166" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111311" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111618" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111418" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111005" />
	 </rdf:Seq>
</items>
<image rdf:resource="http://www.biochemj.org/images/BJ_Name.gif" />
</channel>

<image rdf:about="http://www.biochemj.org/images/BJ_Name.gif">
<title>Biochemical Journal</title>
<url>http://www.biochemj.org/images/BJ_Name.gif</url>
<link>http://www.biochemj.org</link>
</image>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110765">
	<title><![CDATA[Cytosolic Ca2{+} regulates the energisation of isolated brain mitochondria by formation of pyruvate through the malate{-}aspartate shuttle]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110765</link>
	<description><![CDATA[The glutamate-dependent respiration of isolated brain mitochondria (BM) is regulated by cytosolic Ca<sup>2&#x002B;</sup> (Ca<sup>2&#x002B;</sup><sub>cyt</sub>) (S<sub>0.5 </sub>= 225 &#x00B1; 22 nM) through its effects on aralar. We now also demonstrate that the a-glycerophosphate-dependent respiration is controlled by Ca<sup>2&#x002B;</sup><sub>cyt</sub> (S<sub>0.5</sub> = 60 &#x00B1; 10 nM). At higher Ca<sup>2&#x002B;</sup><sub>cyt </sub>(&lt; 600 nM), BM accumulate Ca<sup>2&#x002B;</sup> which enhances the rate of action of intramitochondrial dehydrogenases. The highest Ca<sup>2&#x002B;</sup>-induced increments of state 3 respiration decrease with substrate in the order glutamate &lt; a-ketoglutarate &lt; isocitrate &lt; a-glycerophosphate &lt; pyruvate. Whereas the <i>oxidation </i>of pyruvate is only slightly influenced by Ca<sup>2&#x002B;</sup><sub>cyt</sub>, we show that the <i>formation</i> of pyruvate is tightly controlled by Ca<sup>2&#x002B;</sup><sub>cyt</sub>. Through its common substrate couple NADH/NAD<sup>&#x002B;</sup>, the formation of pyruvate by lactate dehydrogenase (LDH) is linked to the malate&#x2013;aspartate shuttle (MAS) with aralar as a central component. A rise of Ca<sup>2&#x002B;</sup><sub>cyt</sub> in a reconstituted system consisting of BM, cytosolic enzymes of MAS and LDH causes an up to five-fold enhancement of OXPHOS rates that is due to an increased substrate supply, acting in a manner similar to a &#x201C;gas pedal&#x201D;. In contrast, mitochondrial Ca<sup>2&#x002B;</sup> (Ca<sup>2&#x002B;</sup><sub>mit</sub>) regulates the oxidation rates of substrates which are present within mitochondrial matrix.
 
 We postulate that Ca<sup>2&#x002B;</sup><sub>cyt </sub>is a key factor in adjusting the mitochondrial energisation to the requirements of intact neurons.]]></description>
	<dc:creator>F N Gellerich, Z Gizatullina, S Trumbeckaite, B Korzeniewski, T Gaynutdinov, E Seppet, S Vielhaber, H Heinze, F Striggow</dc:creator>
	<dc:date>2012-02-01T16:25:47Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20110765</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-02-01</prism:publicationDate>
	<prism:section>BJ Energy</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112124">
	<title><![CDATA[The antineurodegenerative agent clioquinol regulates the transcription factor FOXO1a]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112124</link>
	<description><![CDATA[Many diseases of ageing including Alzheimer&#x2019;s Disease (AD) and type 2 diabetes (T2D) are strongly associated with common risk factors, such as hypertension, hyperglycaemia and hyperinsulinaemia, suggesting that there may be shared ageing mechanisms underlying these diseases, with scope to identify common cellular targets for therapy. Here we have studied insulin-like signalling properties of an experimental AD 8-hydroxyquinoline drug known as clioquinol. The insulin/IGF-1 signal transduction (IIS) kinase Akt/PKB inhibits the transcription factor FOXO1a by phosphorylating it on residues that trigger its exit from the nucleus and in 293 cells we found that clioquinol treatment induces similar effects. A key transcriptional response to IIS is inhibition of hepatic gluconeogenic gene expression and in rat liver cells, clioquinol represses expression of the key gluconeogenic regulatory enzymes phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase). The effects on FOXO1a and gluconeogenic gene expression require the presence of zinc ions, reminiscent of much earlier literature examining diabetogenic properties of 8-hydroxyquinolines. Comparative investigation of the signalling properties of a panel of these compounds demonstrates that CQ alone exhibits FOXO1a regulation without diabetogenicity. Our results suggest that zinc-dependent regulation of FOXOs and gluconeogenesis may contribute to the therapeutic properties of this drug. Further investigation of this signalling response might illuminate novel pharmacological strategies for the treatment of age-related diseases.]]></description>
	<dc:creator>A R Cameron, K Wallace, L Logie, A R Prescott, T G Unterman, J Harthill, G Rena</dc:creator>
	<dc:date>2012-01-16T14:43:21Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20112124</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-16</prism:publicationDate>
	<prism:section>BJ Disease</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111478">
	<title><![CDATA[Novel structural arrangement of nematode cystathionine beta-synthases: characterization of Caenorhabditis elegans CBS-1]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111478</link>
	<description><![CDATA[Cystathionine beta-synthases are eukaryotic pyridoxal 5'-phosphate (PLP)-dependent proteins that maintain cellular homocysteine homeostasis and produce cystathionine and hydrogen sulfide. In this study, we describe a novel structural arrangement of the cystathionine beta-synthase (CBS) enzyme encoded by the cbs-1 gene of the nematode <i>Caenorhabditis elegans</i>. The CBS-1 protein contains a unique tandem repeat of two evolutionarily conserved catalytic regions in a single polypeptide chain. These repeats include a catalytically active C-terminal module containing a PLP-binding site and a less conserved N-terminal module that is unable to bind the PLP cofactor and cannot catalyze CBS reactions, as demonstrated by analysis of truncated variants and active site-mutant proteins. In contrast to other metazoan enzymes, CBS-1 lacks the heme and the regulatory Bateman domain essential for activation by <i>S</i>-adenosylmethionine and only forms monomers. We determined the tissue and subcellular distribution of CBS-1 and showed that <i>cbs-1</i> knockdown by RNA interference leads to delayed development and to an approximately 10-fold elevation of homocysteine concentrations in nematode extracts. This paper provides the first insight into the metabolism of sulfur amino acids and hydrogen sulfide in <i>C. elegans</i> and shows that nematode cystathionine beta-synthases possess a structural feature that is unique among CBS protein.]]></description>
	<dc:creator>R Vozdek, A Hnizda, J Krijt, M Kostrouchova, V Kozich</dc:creator>
	<dc:date>2012-01-13T12:14:15Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111478</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-13</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111057">
	<title><![CDATA[3{'}-5{'}phosphoadenosine phosphate is an inhibitor of Poly(ADP-ribose) Polymerase 1 and a potential mediator of the lithium-dependent inhibition of PARP-1 in vivo]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111057</link>
	<description><![CDATA[3&#x2019;-5&#x2019;phosphoadenosine phosphate (pAp) is a by-product of sulfur and lipid metabolism and has been shown to have strong inhibitory properties on RNA catabolism. We report here a new target of pAp, Poly(ADP-ribose) Polymerase 1 (PARP-1), a key enzyme in the detection of DNA single strand breaks. We show that pAp can interact with PARP-1 and inhibit its poly(ADP-ribosyl)ation activity. <i>In vitro</i>, inhibition of PARP-1 was detectable at micromolar concentrations of pAp and altered both PARP-1 automodification and heteromodification of histones. Analysis of the kinetic parameters revealed that pAp acted as a mixed inhibitor that modulates both the K<sub>M</sub> and the V<sub>M</sub> of PARP-1. In addition, we showed that upon treatment by lithium, a very potent inhibitor of the enzyme responsible of pAp recycling, HeLa cells exhibited a reduced level of poly(ADP-ribosyl)ation in response to oxidative stress. From these results, we propose that pAp might be a physiological regulator of PARP-1 activity.]]></description>
	<dc:creator>E Toledano, V Ogryzko, A Danchin, D Ladant, U Mechold</dc:creator>
	<dc:date>2012-01-12T14:34:48Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111057</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-12</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111881">
	<title><![CDATA[Phosphate is Not an Absolute Requirement for The Inhibitory Effects of Cyclosporine-A or Cyclophilin-D Deletion on Mitochondrial Permeability Transition]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111881</link>
	<description><![CDATA[Cyclophilin-D (CypD) has been established as a critical regulator of the mitochondrial permeability transition (MPT) pore, and pharmacological or genetic inhibition of CypD attenuates MPT in numerous systems. However, it has recently been suggested that the inhibitory effects of CypD inhibition are only manifest when phosphate (P<sub>i</sub>) is present, and that inhibition is lost when P<sub>i</sub> is substituted with arsenate (As<sub>i</sub>) or vanadate (V<sub>i</sub>). To test this, liver mitochondria were isolated from wildtype and CypD-deficient (<i>Ppif</i><sup>-/-</sup>) mice and then incubated in buffer containing P<sub>i</sub>, As<sub>i</sub>, or V<sub>i</sub>. MPT was induced under both energized and de-energized conditions by addition of Ca<sup>2&#x002B;</sup>, and the resultant mitochondrial swelling measured spectrophotometrically. For pharmacological inhibition of CypD, wildtype mitochondria were pre-incubated with cyclosporine-A (CsA) prior to the addition of Ca<sup>2&#x002B;</sup>. In energized and de-energized mitochondria, Ca<sup>2&#x002B;</sup> induced MPT regardless of the anion present, although the magnitude differed between P<sub>i</sub>, As<sub>i</sub>, and V<sub>i</sub>. However, in all cases, pretreatment with CsA significantly inhibited MPT. Moreover, these effects were independent of mouse strain, organ type, and rodent species. Similarly, attenuation of Ca<sup>2&#x002B;</sup>-induced MPT in the <i>Ppif</i><sup>-/-</sup> mitochondria was still observed irrespective of whether P<sub>i</sub>, As<sub>i</sub>, or V<sub>i</sub> was present. We conclude that the pharmacological and genetic inhibition of CypD is still able to attenuate MPT even in the absence of P<sub>i</sub>.]]></description>
	<dc:creator>A M McGee, C P Baines</dc:creator>
	<dc:date>2012-01-11T16:38:05Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111881</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-11</prism:publicationDate>
	<prism:section>BJ Energy</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112026">
	<title><![CDATA[AMP-activated protein kinase phosphorylates and inactivates liver glycogen synthase]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112026</link>
	<description><![CDATA[Recombinant muscle glycogen synthase-1 (GYS1) and recombinant liver glycogen synthase-2 (GYS2) were phosphorylated by recombinant AMP-activated protein kinase (AMPK) in a time-dependent manner and to a similar stoichiometry. The phosphorylation site in GYS2 was identified as Ser7, which lies in a favorable consensus for phosphorylation by AMPK. Phosphorylation of GYS1 or GYS2 by AMPK led to enzyme inactivation by decreasing the affinity for both UDP-Glc (assayed in the absence of Glc-6-P) and Glc-6-P (assayed at low UDP-Glc concentrations). Incubation of freshly isolated rat hepatocytes with pharmacological AMPK activators 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside (AICA riboside) or A769662 led to persistent GYS inactivation and Ser7 phosphorylation, whereas inactivation by glucagon treatment was transient. In hepatocytes from mice harboring a liver-specific deletion of the AMPK catalytic a1/a2 subunits, GYS2 inactivation by AICA riboside and A769662 was blunted whereas inactivation by glucagon was unaffected. The results suggest that GYS inactivation by AMPK activators in hepatocytes is due to GYS2 Ser7 phosphorylation.]]></description>
	<dc:creator>L Bultot, B Guigas, A Von Wilamowitz-Moellendorff, L Maisin, D Vertommen, N Hussain, M Beullens, J J Guinovart, M Foretz, B Viollet, K Sakamoto, L Hue, M H Rider</dc:creator>
	<dc:date>2012-01-11T12:10:57Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20112026</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-11</prism:publicationDate>
	<prism:section>BJ Signal</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111748">
	<title><![CDATA[Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation.]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111748</link>
	<description><![CDATA[Nutrient deprivation or starvation frequently correlates with amino acid limitation. Amino acid starvation initiates a signal transduction cascade starting with the activation of the kinase GCN2 phosphorylation of eukaryotic initiation factor 2, global protein synthesis reduction and increased activating transcription factor (ATF) 4. ATF4 modulates a wide spectrum of genes involved in the adaptation to dietary stress. The hormone FGF21 is induced during fasting in liver, and its expression induces a metabolic state that mimics long-term fasting. Thus, FGF21 is critical for the induction of hepatic fat oxidation, ketogenesis and gluconeogenesis, metabolic processes which are essential for the adaptive metabolic response to starvation. In this article, we show that FGF21 is induced by amino acid deprivation in both mouse liver and HepG2 cultured cells. We have identified the human <i>FGF21</i> gene as a target gene for ATF4 and we have localized two conserved ATF4 binding sequences in the 5&#x2019; regulatory region of the human <i>FGF21</i> gene, which are responsible for the ATF4-dependent transcriptional activation of this gene. These results add <i>FGF21</i> gene induction to the transcriptional program initiated by increased levels of ATF4 and offer a new mechanism for the induction of the <i>FGF21</i> gene expression under nutrient deprivation.]]></description>
	<dc:creator>A De Sousa-Coelho, P F. Marrero, D Haro</dc:creator>
	<dc:date>2012-01-11T12:04:15Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111748</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-11</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111509">
	<title><![CDATA[Catalytic residues and a predicted structure of tetrahydrobiopterin-dependent alkylglycerol monooxygenase]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111509</link>
	<description><![CDATA[Alkylglycerol monooxygenase (E.C. 1.14.16.5) forms a third, distinct class among tetrahydrobiopterin-dependent enzymes in addition to aromatic amino acid hydroxylases and nitric oxide synthases. Its protein sequence contains the fatty acid hydroxylase motif, a signature indicative of a diiron centre, which comprises eight conserved histidines. Membrane enzymes containing this motif, including alkylglycerol monooxygenase, are especially labile and could not be purified to homogeneity in active form so far. To get a first insight on structure-function relationships of this enzyme, we performed site-directed mutagenesis of 26 selected amino acid residues and expressed wild type and mutant proteins containing a C-terminal myc tag together with fatty aldehyde dehydrogenase in Chinese hamster ovary cells. Among all acidic residues within the eight-histidine motif, only mutation of glutamate 137 to alanine led to an 18-fold increase in the Michaelis Menten constant for tetrahydrobiopterin, suggesting a role in tetrahydrobiopterin interaction. A ninth additional histidine essential for activity was identified. Nine membrane domains were predicted by 4 programs ESKW, TMHMM, MEMSAT and Phobius. Prediction of a part of the structure using Rosetta-Membrane <i>ab initio</i> method led to a plausible suggestion for a structure of the catalytic site of alkylglycerol monooxygenase.]]></description>
	<dc:creator>K Watschinger, J E Fuchs, V Yarov-Yarovoy, M A Keller, G Golderer, A Hermetter, G Werner-Felmayer, N Hulo, E R Werner</dc:creator>
	<dc:date>2012-01-06T10:56:42Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111509</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-06</prism:publicationDate>
	<prism:section>BJ Structure</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111530">
	<title><![CDATA[Identification of autophosphorylation sites in eukaryotic elongation factor-2 kinase]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111530</link>
	<description><![CDATA[Eukaryotic elongation factor 2 kinase (eEF2K) phosphorylates and inactivates the translation elongation factor eEF2. eEF2K is not a member of the main eukaryotic protein kinase superfamily but instead belongs to a small group of so-called a-kinases. The activity of eEF2K is normally dependent upon Ca<sup>2&#x002B;</sup> and calmodulin. 
 eEF2K has previously been shown to undergo autophosphorylation, the stoichiometry of which suggested the existence of multiple sites. Here we identified several autophosphorylation sites including Thr-348, Thr-353, Ser-366 and Ser-445, all of which are highly conserved among vertebrate eEF2Ks. We also identified a number of other sites, including Ser-78, a known site of phosphorylation, and others, some of which are less well conserved. None of the sites lies in the catalytic domain, but three affect eEF2K activity. Mutation of Ser-78, Thr-348 and Ser-366 to a non-phosphorylatable alanine residue decreased eEF2K activity. 
 Phosphorylation of Thr-348 was detected by immunoblotting after transfecting wild-type eEF2K into HEK 293 cells, but not after transfection with a kinase-inactive construct confirming that it is indeed a site of autophosphorylation. Thr-348 appears to be constitutively autophosphorylated <i>in vitro.</i> Interestingly, other recent data suggest that the corresponding residue in other a-kinases is also autophosphorylated and contributes to the activation of these enzymes (Crawley et al., <i>J. Biol. Chem</i>. 2011, <b>286</b>, 2607-2616). Ser-366 phosphorylation was also detected in intact cells, but was still observed in the kinase-inactive construct, demonstrating that this site is not only phosphorylated autocatalytically but also in <i>trans</i> by other kinases.]]></description>
	<dc:creator>S Pyr Dit Ruys, X Wang, E M Smith, G Herinckx, N Hussain, M H Rider, D Vertommen, C Gregory Proud</dc:creator>
	<dc:date>2012-01-04T15:16:12Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111530</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-04</prism:publicationDate>
	<prism:section>BJ Signal</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111280">
	<title><![CDATA[Fructose 2,6-bisphosphate is essential for glucose-regulated gene transcription of glucose 6-phosphatase and other ChREBP target genes in hepatocytes]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111280</link>
	<description><![CDATA[Glucose metabolism in the liver activates transcription of various genes encoding enzymes of glycolysis and lipogenesis and also glucose 6-phosphatase (G6pc). Allosteric mechanisms involving glucose 6-P or xylulose 5-P and covalent modification of ChREBP have been implicated in this mechanism. However evidence supporting an essential role for a specific metabolite or pathway in hepatocytes remains equivocal. By using diverse substrates and inhibitors and a kinase-deficient bisphosphatase-active variant of the bifunctional enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK2/FBP2), we demonstrate an essential role for fructose 2,6-bisphosphate in the induction of G6pc and other ChREBP target genes by glucose. Selective depletion of fructose 2,6-bisphosphate inhibits glucose-induced recruitment of ChREBP to the G6pc promoter and also induction of G6pc by xylitol and gluconeogenic precursors. The requirement for fructose 2,6-bisphosphate for ChREBP recruitment to the promoter does not exclude involvement of additional metabolites acting either co-ordinately or at downstream sites. Glucose raises fructose 2,6-bisphosphate in hepatocytes by reversing the phosphorylation of PFK2/FBP2 at ser32 but also independently of ser32 dephosphorylation. This supports a role for the bifunctional enzyme as the phosphometabolite sensor and for its product, fructose 2,6-bisphosphate, as the metabolic signal for substrate-regulated ChREBP-mediated expression of G6pc and other ChREBP target genes.]]></description>
	<dc:creator>C Arden, S J Tudhope, J L Petrie, Z H Al-Oanzi, K S Cullen, A J. Lange, H C Towle, L Agius</dc:creator>
	<dc:date>2012-01-03T16:07:36Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111280</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-03</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111648">
	<title><![CDATA[Transcriptional control of glyoxalase 1 by Nrf2 provides a stress responsive defence against dicarbonyl glycation]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111648</link>
	<description><![CDATA[Abnormal cellular accumulation of the dicarbonyl metabolite methylglyoxal occurs on exposure to high glucose concentration, inflammation, cell ageing and senescence. It is associated with increased methylglyoxal-adduct content of protein and DNA linked to increased DNA strand breaks and mutagenesis, mitochondrial dysfunction and reactive oxygen species formation and cell detachment from the extracellular matrix. Methylglyoxal&#x2013;mediated damage is countered by glutathione-dependent metabolism by glyoxalase-1. It is not known, however, if glyoxalase-1 has stress responsive up-regulation to counter periods of high methylglyoxal concentration or dicarbonyl stress. We identified a functional antioxidant response element in the 5&#x2019;-untranslated region of exon-1 of the mammalian glyoxalase-1 gene. Transcription factor Nrf2 binds to this antioxidant response element increasing basal and inducible expression of glyoxalase 1. Activators of Nrf2 induced increased glyoxalase-1 mRNA, protein and activity. Increased expression of glyoxalase-1 decreased cellular and extracellular concentrations of methylglyoxal, methylglyoxal -derived protein adducts, mutagenesis and cell detachment. Hepatic, brain, heart, kidney and lung glyoxalase-1 mRNA and protein were decreased in Nrf2 (-/-) mice and urinary excretion of methylglyoxal protein and nucleotide adducts were increased <i>ca.</i> 2-fold. We conclude that dicarbonyl stress is countered by up-regulation of glyoxalase-1 in the Nrf2 stress responsive system, protecting protein and DNA from increased damage and preserving cell function.]]></description>
	<dc:creator>M Xue, N Rabbani, H Momiji, P Imbasi, M Anwar, N Kitteringham, K Park, T Souma, T MORIGUCHI, M Yamamoto, P J. Thornalley</dc:creator>
	<dc:date>2011-12-22T10:54:17Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111648</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-22</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111420">
	<title><![CDATA[THE HUMAN GENE SLC25A17 ENCODES A PEROXISOMAL TRANSPORTER OF COENZYME A, FAD AND NAD{+}]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111420</link>
	<description><![CDATA[The essential cofactors coenzyme A (CoA), FAD and NAD<sup>&#x002B;</sup> are synthesized outside the peroxisomes and therefore must be transported into the peroxisomal matrix where they are required for important processes. In this work we have functionally identified and characterized SLC25A17, which is the only member of the mitochondrial carrier family that has previously been shown to be localized in the peroxisomal membrane. Herein, recombinant and purified SLC25A17 was reconstituted into liposomes. Its transport properties and kinetic parameters demonstrate that SLC25A17 is a transporter of CoA, FAD, FMN, AMP and to a lesser extent of NAD<sup>&#x002B;</sup>, adenosine 3&#x2019;,5&#x2019;-diphosphate (PAP) and ADP. SLC25A17 functioned almost exclusively by a counter-exchange mechanism, was saturable and inhibited by pyridoxal-5&#x2019;-phosphate and other mitochondrial carrier inhibitors. It was expressed to various degrees in all the human tissues examined. Its main function is probably to transport free CoA, FAD and NAD<sup>&#x002B;</sup> into peroxisomes in exchange for intraperoxisomally generated PAP, FMN and AMP. This is the first report describing the identification and characterization of a transporter for multiple free cofactors in peroxisomes.]]></description>
	<dc:creator>G Agrimi, A Russo, P Scarcia, F Palmieri</dc:creator>
	<dc:date>2011-12-21T12:58:16Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111420</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-21</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111849">
	<title><![CDATA[Novel Sterol Metabolic Network of Trypanosoma brucei Procyclic and Bloodstream Forms]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111849</link>
	<description><![CDATA[<i>Trypanosoma brucei </i>is the protozoan parasite that causes African trypanosomiasis, a neglected disease of people and animals. Co-metabolite analysis, labeling studies using [<i>methyl</i>-<sup>2</sup>H<sub>3</sub>]methionine and substrate/product-specificities of the cloned sterol C24-methyl transferase (24-SMT) and sterol C14-demethylase (14-SDM) from <i>T. brucei</i> afforded an uncommon sterol metabolic network that proceeds from lanosterol and 31-norlanosterol to ergosta-5,7,25(27)-trien-3&#x03B2;-ol (ETO), 24-dimethyl ergosta-5,7,25(27)-trienol (DTO) and ergosta-5,7,22(23)-trienol (ergosterol). To assess the possible carbon sources of ergosterol biosynthesis, specifically <sup>13</sup>C-labeled specimens of lanosterol, acetate, leucine and glucose were administered to <i>T. brucei</i> and the <sup>13</sup>C distributions found were in accord with the operation of the acetate-mevalonate pathway, with leucine as an alternate precursor, to ergostenols in either the insect or bloodstream form. In searching for metabolic signatures of procyclic cells, we observed that the <sup>13</sup>C-labeling treatments induce fluctuations between the acetyl-CoA (mitochondrial) and sterol (cytosolic) synthetic pathways detected in the progressive increase in <sup>13</sup>C-ergosterol production (control &lt; [2-<sup>13</sup>C]leucine &lt; [2-<sup>13</sup>C]acetate &lt; [1-<sup>13</sup>C]glucose) and corresponding depletion of cholesta-5,7,24-trienol. We conclude that anabolic fluxes originating in mitochondrial metabolism constitute a flexible part of sterol synthesis that is further fluctuated in the cytosol yielding distinct sterol profiles in relation to cell demands on growth.]]></description>
	<dc:creator>C Robert Nes, U K Singha, J Liu, K Ganapathy, F Villalta, M R. Waterman, G I Lepesheva, M Chaudhuri, W David Nes</dc:creator>
	<dc:date>2011-12-19T12:18:58Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111849</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-19</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112037">
	<title><![CDATA[I{kappa}B Kinase {beta} (IKK{beta}) does not mediate feedback inhibition of the insulin-signaling cascade]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112037</link>
	<description><![CDATA[Herein, we have examined whether I&#x03BA;B Kinase &#x03B2; (IKK&#x03B2;) plays a role in feedback inhibition of the insulin-signaling cascade. Insulin induces the phosphorylation of IKK&#x03B2;, <i>in vitro</i> and <i>in vivo</i>, and this effect is dependent on intact signaling via phosphatidylinositol 3-kinase (PI3K), but not protein kinase B (PKB). To test the hypothesis that insulin activates IKK&#x03B2; as a means of negative feedback, we employed a variety of experimental approaches. Firstly, pharmacological inhibition of IKK&#x03B2; via BMS-345541 did not potentiate insulin-induced IRS1 tyrosine phosphorylation, PKB phosphorylation or 2-deoxyglucose uptake in differentiated 3T3-L1 adipocytes. BMS-345541 did not prevent insulin-induced IRS1 serine phosphorylation on known IKK&#x03B2; target sites. Secondly, adenoviral-mediated over-expression of wild type (WT) IKK&#x03B2; in differentiated 3T3-L1 adipocytes did not suppress insulin-stimulated 2-deoxyglucose uptake, insulin receptor substrate 1 (IRS1) tyrosine phosphorylation, IRS1 association with the p85 regulatory subunit of PI3K or PKB phosphorylation. Thirdly, insulin signaling was not potentiated in mouse embryo fibroblasts lacking IKK&#x03B2; (<i>Ikk&#x03B2;<sup>-/-</sup></i> MEF). Finally, insulin treatment of 3T3-L1 adipocytes did not promote the recruitment of IKK&#x03B2; to IRS1, supporting our data that IKK&#x03B2;, while activated by insulin, does not promote direct serine phosphorylation of IRS1 and does not contribute to the feedback inhibition of the insulin-signaling cascade.]]></description>
	<dc:creator>G I Lancaster, B Skiba, C Yang, H T Nicholls, K G Langley, M Chan, C R Bruce, G W Rewcastle, P R Shepherd, M Karin, M A. Febbraio</dc:creator>
	<dc:date>2011-12-14T12:16:28Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20112037</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-14</prism:publicationDate>
	<prism:section>BJ Signal</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111796">
	<title><![CDATA[Plastoquinone-9 biosynthesis in cyanobacteria differs from that in plants and involves a novel 4-hydroxybenzoate solanesyltransferase]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111796</link>
	<description><![CDATA[Plastoquinone-9 (PQ-9) has a central role in the energy transformation processes in cyanobacteria by mediating electron transfer in both, the photosynthetic as well as the respiratory electron transport chain. The present study provides evidence that the PQ-9 biosynthetic pathway in cyanobacteria substantially differs from that in plants. We identified 4-hydroxybenzoate as being the aromatic precursor for PQ-9 in <i>Synechocystis</i> sp. PCC6803 and report here on the role of the membrane-bound 4-hydroxybenzoate solanesyltransferase, Slr0926, in PQ-9 biosynthesis and on the properties of the enzyme. The catalytic activity of Slr0926 was demonstrated by <i>in vivo</i> labelling experiments in <i>Synechocystis</i> sp., complementation studies in an <i>E. coli</i> mutant with a defect in ubiquinone biosynthesis as well as by <i>in vitro</i> assays using the recombinant as well as the native enzyme. While Slr0926 was highly specific for the prenyl acceptor substrate, 4-hydroxybenzoate, it displayed a broad specificity with regard to the prenyl donor substrate and used not only solanesyl diphosphate (SPP) but also a number of shorter-chain prenyl diphosphates. In combination with <i>in silico</i> data, our results indicate that Slr0926 evolved from bacterial 4-hydroxybenzoate prenyltransferase catalysing prenylation in the course of ubiquinone biosynthesis.]]></description>
	<dc:creator>R Sadre, C Pfaff, S Buchkremer</dc:creator>
	<dc:date>2011-12-14T11:13:05Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111796</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-14</prism:publicationDate>
	<prism:section>BJ Plant</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111166">
	<title><![CDATA[Selective reduction of hydroperoxyeicosatetraenoic acids to their hydroxy derivatives by apolipoprotein-D: Implications for lipid antioxidant activity and Alzheimer{'}s disease]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111166</link>
	<description><![CDATA[Apolipoprotein-D (apoD) is upregulated in Alzheimer&#x2019;s disease (AD) and upon oxidative stress. ApoD inhibits brain lipid peroxidation in vivo but the mechanism is unknown. Specific Met residues may inhibit lipid peroxidation by reducing radical-propagating lipid hydroperoxides to non-reactive hydroxides via a reaction that generates methionine sulfoxide (MetSO). Since apoD has three conserved Met residues (M49, M93, M157), we generated recombinant proteins with either one or all Met residues replaced by Ala and assessed their capacity to reduce hydroperoxyeicosatetraenoic acids (HpETEs) to their hydroxyeicosatetraenoic acid (HETE) derivatives. ApoD, apoD(M49-A) and apoD(M157-A) all catalysed the reduction of HpETEs to their corresponding HETEs. Amino acid analysis of HpETE-treated apoD revealed a loss of one third of the Met residues accompanied by the formation of MetSO. Additional studies using apoD(M93-A) indicated M93 was required for HpETE reduction. We also assessed the impact that apoD MetSO formation has on protein aggregation by Western blotting of HpETE-treated apoD and human brain samples. ApoD Met oxidation was associated with formation of apoD aggregates that were also detected in AD hippocampus. In conclusion, conversion of HpETE to HETE is mediated by apoD M93, a process that may contribute to apoD antioxidant function.]]></description>
	<dc:creator>S Bhatia, B Knoch, J Wong, W Scott Kim, P L. Else, A J Oakley, B Garner</dc:creator>
	<dc:date>2011-12-12T15:05:50Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111166</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-12</prism:publicationDate>
	<prism:section>BJ Disease</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111311">
	<title><![CDATA[A Golgi-localized MATE transporter mediates iron homeostasis under osmotic stress in Arabidopsis]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111311</link>
	<description><![CDATA[Iron is an essential micronutrient that acts as a cofactor in a wide variety of pivotal metabolic processes, such as electron transport chain of respiration, photosynthesis, and redox reactions, in plants. However, its overload exceeding the cellular capacity of iron binding and storage is potentially toxic to plant cells by causing oxidative stress and cell death. Consequently, plants have developed versatile mechanisms to maintain iron homeostasis. Organismal iron content is tightly regulated at the steps of uptake, translocation, and compartmentalization. Whereas iron uptake is fairly well understood at the cellular and organismal levels, intracellular and intercellular transport is only poorly understood. Here, we show that a multidrug and toxic compound extrusion (MATE) transporter, designated BCD1, contributes to iron homeostasis during stress responses and senescence in <i>Arabidopsis</i>. The <i>BCD1</i> gene is induced by excessive iron but repressed by iron deficiency. It is also induced by cellular and tissue damages occurring under osmotic stress. The activation-tagged mutant <i>bcd1-1D</i> exhibits leaf chlorosis, typical symptom of iron deficiency. The chlorotic lesion of the mutant was partially recovered by iron feeding. Whereas the <i>bcd1-1D</i> mutant accumulated a lower amount of iron, the iron level was elevated in the knockout mutant <i>bcd1-1</i>. The BCD1 protein is localized to the Golgi complex. We propose that the BCD1 transporter plays a role in sustaining iron homeostasis by reallocating excess iron released from stress-induced cellular damages.]]></description>
	<dc:creator>P Seo, J Park, M Park, Y Kim, S Kim, J Jung, C Park</dc:creator>
	<dc:date>2011-12-08T11:38:33Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111311</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-08</prism:publicationDate>
	<prism:section>BJ Plant</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111618">
	<title><![CDATA[Lactococcus lactis HemW (HemN) is a heme-binding protein with a putative role in heme trafficking]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111618</link>
	<description><![CDATA[<i>Lactococcus lactis</i> cannot synthesize heme, but when supplied with heme, expresses a cytochrome <i>bd</i> oxidase. Aside of the <i>cydAB</i> structural genes for this oxidase, <i>L. lactis</i> features two additional genes, <i>hemH</i> and <i>hemW</i> (<i>hemN</i>), with conjectured functions in heme metabolism. While it appears clear that <i>hemH </i>encodes a ferrochelatase, no function is know for <i>hemW</i>. HemW-like proteins occur in bacteria, plants, and animals, and are usually annotated as coproporphyrinogen III dehydrogenases. However, such a function has never been demonstrated for a HemW-like protein. We here studied HemW of <i>L. lactis</i> and showed that it is devoid of coproporphyrinogen III dehydrogenase activity <i>in vivo</i> and <i>in vitro</i>. Recombinantly produced, purified HemW contained an iron-sulfur cluster and was dimeric; upon loss of the iron, the protein became monomeric. Both forms of the protein covalently bound heme <i>b</i> <i>in vitro</i>, with a stoichiometry of one heme per monomer and a K<sub>D</sub> of 8 &#x00B5;M. <i>In vivo</i>, HemW occurred as a heme free, cytosolic form, as well as a heme-containing, membrane-associated form. Addition of <i>L. lactis</i> membranes to heme-containing HemW triggered the release of heme from HemW <i>in vitro</i>. Based these findings, we propose a role of HemW in heme trafficking. HemW-like proteins form a distinct phylogenetic clade which has not previously been recognized.]]></description>
	<dc:creator>H K Abicht, J Martinez, G Layer, D Jahn, M Solioz</dc:creator>
	<dc:date>2011-12-05T14:10:46Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111618</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-05</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111418">
	<title><![CDATA[PROGESTINS ACTIVATE 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE (PFKFB3) IN BREAST CANCER CELLS]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111418</link>
	<description><![CDATA[6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB) catalyzes the synthesis and degradation of fructose-2,6-bisphosphate (Fru-2,6-P<sub>2</sub>), a key modulator of glycolysis and gluconeogenesis. <i>PFKFB3</i> gene is extensively involved in cell proliferation due to its key role in carbohydrate metabolism. Here we analyse its mechanism of regulation by progestins in breast cancer cells. We report that exposure of T47D cells to synthetic progestins (ORG2058 or Norgestrel) leads to a rapid increase in Fru-2,6-P<sub>2</sub> concentration. Western blot results are compatible with a short-term activation due to PFKFB3 isoenzyme phosphorylation and a long-term sustained action due to increased PFKFB3 protein levels. Transient transfection of T47D cells with deleted gene promoter constructs allowed us to identify a progesterone regulatory element (PRE) to which progesterone receptor binds and thus transactivates <i>PFKFB3</i> gene transcription. Progesterone Receptor (PR) expression, in the PR-negative cell line (MDA-MB-231), induces endogen <i>PFKFB3</i> expression in response to Norgestrel. Direct Binding of PR to the PRE box (-3490 nt) was confirmed by ChIP experiments. A dual mechanism affecting PFKFB3 protein and gene regulation operates in order to assure glycolysis in breast cancer cells. An immediate early response through the ERK-RSK pathway leading to phosphorylation of PFKFB3 on Ser 461 is followed by activation of mRNA transcription via <i>cis</i>-acting sequences on <i>PFKFB3 </i>promoter.]]></description>
	<dc:creator>L Novellasdemunt, M Obach, L Mill&#x00E1;n-Ari&#x00F1;o, A Manzano, F Ventura, J Rosa, A Jordan, A Navarro-Sabate, R Bartrons</dc:creator>
	<dc:date>2011-11-24T14:08:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111418</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-11-24</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111005">
	<title><![CDATA[ALAS-1 gene expression is down-regulated by Akt-mediated phosphorylation and nuclear exclusion of FOXO1 by vanadate in diabetic mice.]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111005</link>
	<description><![CDATA[<b> <b>Porphyrias are diseases caused by partial deficiencies of haem biosynthesis enzymes. Acute porphyrias are characterized by a neuropsychiatric syndrome with intermittent induction of hepatic </b><b>&#x03B4;</b><b>-aminolevulinate synthase 1 (ALAS-1), first and rate-limiting enzyme of haem pathway.</b>
<b>Porphyria acute attacks are usually treated with glucose administration, its effect is apparently related to its ability of inhibiting ALAS-1 by modulating insulin plasma levels. It was shown that insulin blunts hepatocytes ALAS-1 induction, by disrupting the interaction of the Forkhead box O1 (FOXO1) and the proliferator-activated receptor &#x03B3; coactivator 1&#x03B1; (PGC-1&#x03B1;).</b>
<b>We evaluated the expression of ALAS-1 in a murine model of diabetes and determined the effects of the insulinomimetic vanadate, on the enzyme regulation to evaluate its potential for the treatment of porphyria acute attacks. Both </b><b>ALAS-1 mRNA and </b><b>protein content were induced </b><b>in d</b><b>iabetic animals, accompanied by </b><b>decreased Akt phosphorylation and </b><b>increased nuclear FOXO1, PGC-1&#x03B1; and FOXO1-PGC-1&#x03B1; complex. Vanadate reversed ALAS-1 induction with a concomitant PI3K/Akt pathway activation and subsequent reduction of nuclear FOXO1, PGC-1&#x03B1; and FOXO1-PGC-1&#x03B1; complex levels.</b>
<b>These finding support that the FOXO1-PGC-1&#x03B1; complex is involved in the control of ALAS-1 expression and further suggest that a vanadate-based therapy could be beneficial for the treatment of porphyria acute attacks.</b>
</b>]]></description>
	<dc:creator>L Maria Oliveri, C Davio, A Mar&#x00ED;a del C&#x00E1;rmen Batlle, E Noemi Gerez</dc:creator>
	<dc:date>2011-11-10T09:13:02Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111005</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-11-10</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>



</rdf:RDF>

